TY - JOUR
T1 - A scoping review of cost-effectiveness of screening and treatment for latent tuberculosis infection in migrants from high-incidence countries
AU - COHEMI project study group
AU - Zammarchi, Lorenzo
AU - Casadei, Gianluigi
AU - Strohmeyer, Marianne
AU - Bartalesi, Filippo
AU - Liendo, Carola
AU - Matteelli, Alberto
AU - Bonati, Maurizio
AU - Gotuzzo, Eduardo
AU - Bartoloni, Alessandro
AU - Pandolfini, Chiara
AU - Severino, Francesca
AU - Confalonieri, Valeria
AU - Tognoni, Gianni
AU - Bisoffi, Zeno
AU - Buonfrate, Dora
AU - Angheben, Andrea
AU - Albonico, Marco
AU - Muñoz, Jose
AU - Requena-Mendez, Ana
AU - Roura, Maria
AU - Ventura, Laia
AU - Pool, Robert
AU - Pell, Christopher
AU - Hardon, Anita
AU - Chiodini, Peter
AU - Moreira, Juan
AU - Anselmi, Mariella
AU - Sempértegui, Roberto
AU - Mena, Maria Alejandra
AU - Garcia, Héctor H.
AU - Bustos, Javier
AU - Santivañez, Saul
AU - Torrico, Faustino
AU - Lozano, Daniel
AU - Cabrera, Teresa Hinojosa
AU - Morón, Javier Ochoa
AU - AbaporiCuellar, Ignacio
AU - Suarez, Jaime Amorós
AU - ChumirayRojas, Guido
AU - Nicoletti, Alessandra
AU - Bruno, Elisa
N1 - Publisher Copyright:
© 2015 Zammarchi et al.
PY - 2015/9/24
Y1 - 2015/9/24
N2 - Background: In low-incidence countries, most tuberculosis (TB) cases occur among migrants and are caused by reactivation of latent tuberculosis infection (LTBI) acquired in the country of origin. Diagnosis and treatment of LTBI are rarely implemented to reduce the burden of TB in immigrants, partly because the cost-effectiveness profile of this intervention is uncertain. The objective of this research is to perform a review of the literature to assess the cost-effectiveness of LTBI diagnosis and treatment strategies in migrants. Methods: Scoping review of economic evaluations on LTBI screening strategies for migrants was carried out in Medline. Results: Nine studies met the inclusion criteria. LTBI screening was cost-effective according to seven studies. Findings of four studies support interferon gamma release assay as the most cost-effective test for LTBI screening in migrants. Two studies found that LTBI screening is cost-effective only if carried out in immigrants who are contacts of active TB cases. Discussion and Conclusions: Our findings support the cost-effectiveness of LTBI diagnostic and treatment strategies in migrants especially if they are focused on young subjects from high incidence countries. These strategies could represent and adjunctive and synergistic tool to achieve the ambitious aim of TB elimination.
AB - Background: In low-incidence countries, most tuberculosis (TB) cases occur among migrants and are caused by reactivation of latent tuberculosis infection (LTBI) acquired in the country of origin. Diagnosis and treatment of LTBI are rarely implemented to reduce the burden of TB in immigrants, partly because the cost-effectiveness profile of this intervention is uncertain. The objective of this research is to perform a review of the literature to assess the cost-effectiveness of LTBI diagnosis and treatment strategies in migrants. Methods: Scoping review of economic evaluations on LTBI screening strategies for migrants was carried out in Medline. Results: Nine studies met the inclusion criteria. LTBI screening was cost-effective according to seven studies. Findings of four studies support interferon gamma release assay as the most cost-effective test for LTBI screening in migrants. Two studies found that LTBI screening is cost-effective only if carried out in immigrants who are contacts of active TB cases. Discussion and Conclusions: Our findings support the cost-effectiveness of LTBI diagnostic and treatment strategies in migrants especially if they are focused on young subjects from high incidence countries. These strategies could represent and adjunctive and synergistic tool to achieve the ambitious aim of TB elimination.
UR - http://www.scopus.com/inward/record.url?scp=84942156014&partnerID=8YFLogxK
U2 - 10.1186/s12913-015-1045-3
DO - 10.1186/s12913-015-1045-3
M3 - Review article
C2 - 26399233
AN - SCOPUS:84942156014
SN - 1472-6963
VL - 15
JO - BMC Health Services Research
JF - BMC Health Services Research
IS - 1
M1 - 412
ER -